Congress slowly processes appropriations bills to fund the government, including Executive Branch tax functions.

The United States Attorney’s Office for the District of South Carolina filed a qui tam intervenor complaint under the False Claims Act alleging that a South Carolina office furniture company, Global ...

Yesterday, the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) announced the withdrawal of its proposed Corporate Governance Framework for U.S. public companies to consider ...

On July 14, 2025, the federal banking regulators issued a joint statement for banking organizations that provide or are considering providing safekeeping for crypto-assets in a fiduciary or ...

On July 2, 2025, DOJ’s Civil Division and HHS issued a joint press release announcing the reestablishment of the DOJ-HHS False Claims Act Working Group.

CarUX Holding has agreed to acquire all of the shares in Pioneer Corporation from global investment firm EQT. The purchase price reflects an equity value of ¥163.6 billion (approximately $1.1 billion) ...

On June 16, 2025, the Senate Finance Committee released its version of the tax provisions in the “One Big, Beautiful Bill.” The SFC version makes many modifications to the House Bill, including a ...

Reinsurance Group of America (RGA), a leading global provider of traditional life and health reinsurance and financial solutions, established a contingent liquidity facility through the issuance of ...

Tax policy update for week of June 9 Senate GOP considers next steps on OBBBA Treasury Secretary Bessent will testify Wednesday and Thursday at the tax writing committees on the Administration’s ...

In the 2025 edition of Chambers USA, S&C lawyers received 148 individual rankings, including 38 Band 1 rankings, denoting top performers in their field. Four S&C lawyers were newly ranked, and S&C ...

COSO and NACD have released a public exposure draft of a proposed Corporate Governance Framework for U.S. public companies.

Boston Pharmaceuticals, a portfolio company of B-Flexion, agreed to sell its lead asset, efimosfermin alfa, a phase III-ready, potential best-in-class, investigational specialty medicine to treat and ...